{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:20:01Z","timestamp":1787772001573,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Rabies presents with a high fatality rate, which imposes a significant global public health challenge, and therefore the use of post-exposure prophylaxis (PEP) is crucial for prevention. Monoclonal antibodies (mAbs) have emerged as a promising substitute for rabies immunoglobulins (RIGs) due to their high efficacy and standardized manufacturing process. A prospective, open-label, post-marketing surveillance study (PMS) was conducted at Byramjee Jeejeebhoy Medical College (BJMC), Pune. The study included patients aged more than 2 years who had recently sustained Category III-suspected rabid animal bite exposures. These patients were administered TwinRabTM at a dosage of 40 IU\/kg in and around the wound as intralesional transfer, along with the anti-rabies vaccine (ARV). Adverse events (AEs) grading was performed with reference to the Food and Drug Administration (FDA) toxicity grading. In this study, 215 subjects received the TwinRabTM mAb with a 100% completion rate. Out of 215 patients, three (1.3%) patients in the range of 18 to 65 years of age showed solicited local AEs, which were resolved after the appropriate treatment intervention, but causality assessment was non-assessable. The overall tolerability assessment showed positive ratings from doctors (91.63%) and patients (67.91%) for the mAb cocktail. The PMS demonstrated the safety of TwinRabTM in patients who experienced Category III-suspected rabid animal bites, thereby supporting its potential as an alternative option for post-exposure prophylaxis in the management of animal bites for the prevention of rabies<\/jats:p>","DOI":"10.4103\/ijcm.ijcm_562_23","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T04:02:33Z","timestamp":1709870553000},"page":"443-447","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Post-Marketing Surveillance of the World\u2019s First Novel Cocktail of Rabies Monoclonal Antibodies: TwinRab\u2122 in Real \\-World Setting"],"prefix":"10.4103","volume":"49","author":[{"given":"Muralidhar P.","family":"Tambe","sequence":"first","affiliation":[{"name":"BJ Government Medical College, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malangori A.","family":"Parande","sequence":"additional","affiliation":[{"name":"BJ Government Medical College, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh B.","family":"Nanaware","sequence":"additional","affiliation":[{"name":"BJ Government Medical College, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandkumar M.","family":"Salunke","sequence":"additional","affiliation":[{"name":"BJ Government Medical College, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trayambak","family":"Dutta","sequence":"additional","affiliation":[{"name":"Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"R1-20260330","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/vr.h4196","article-title":"Rabies: 100 per cent fatal, 100 per cent preventable","volume":"177","author":"Abela-Ridder","year":"2015","journal-title":"Vet Rec"},{"key":"R2-20260330","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1371\/journal.pntd.0001847","article-title":"Deaths from symptomatically identifiable furious rabies in India: A nationally representative mortality survey","volume":"6","author":"Suraweera","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"R3-20260330","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","article-title":"Assessing the burden of human rabies in India: Results of a national multi-center epidemiological survey","volume":"11","author":"Sudarshan","year":"2007","journal-title":"Int J Infect Dis"},{"key":"R4-20260330","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0042-6822(87)90167-X","article-title":"Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies","volume":"161","author":"Dietzschold","year":"1987","journal-title":"Virology"},{"key":"R5-20260330","doi-asserted-by":"crossref","first-page":"2081024","DOI":"10.1080\/21645515.2022.2081024","article-title":"Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures","volume":"18","author":"Haradanhalli","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R6-20260330","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R8-20260330","doi-asserted-by":"crossref","first-page":"2026713","DOI":"10.1080\/21645515.2022.2026713","article-title":"Advances in the progress of monoclonal antibodies for rabies","volume":"18","author":"Fan","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R9-20260330","doi-asserted-by":"crossref","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","article-title":"A phase 3, randomized, open-label, noninferiority trial evaluating anti-rabies monoclonal antibody cocktail (TwinRabTM) against human rabies immunoglobulin (HRIG)","volume":"73","author":"Kansagra","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R10-20260330","first-page":"196","article-title":"Defining the volume of rabies immunoglobulins\/rabies monoclonal antibodies requirement for wound infiltration of category III animal exposures \u2013An exploratory study","volume":"30","author":"Haradanhalli","year":"2021","journal-title":"Indian Journal of Community Health"},{"key":"R11-20260330","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1080\/21645515.2021.2013079","article-title":"Defining the volume of rabies immunoglobulins\/rabies monoclonal antibodies requirement for wound infiltration of category III animal exposures \u2013An exploratory study","volume":"17","author":"Haradanhalli","year":"2021","journal-title":"Hum Vaccin Immunother"}],"container-title":["Indian Journal of Community Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_562_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:24:54Z","timestamp":1787768694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_562_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijcm.ijcm_562_23","relation":{},"ISSN":["0970-0218","1998-3581"],"issn-type":[{"value":"0970-0218","type":"print"},{"value":"1998-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}